Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Pharmaceutical composition for prevention or treatment of kidney damage

A composition and technology for acute kidney injury, applied in the direction of drug combination, drug delivery, medical preparations containing active ingredients, etc., can solve problems affecting organ damage and protection

Pending Publication Date: 2021-03-09
KANAZAWA UNIV +1
View PDF7 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, there is no record or revelation about the damage and protection of organs caused by D-amino acids derived from intestinal bacteria

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical composition for prevention or treatment of kidney damage
  • Pharmaceutical composition for prevention or treatment of kidney damage
  • Pharmaceutical composition for prevention or treatment of kidney damage

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0071] Example 1: Induction of renal injury by ischemia-reperfusion

[0072] 1. Materials and Methods

[0073] (1) Research ethics

[0074] All experiments were performed in accordance with facility guidelines and were approved by the facility's Animal Experimentation Committee.

[0075] (2) Material

[0076] Amino acid enantiomers and HPLC grade acetonitrile were purchased from Nakalai Tesque (Kyoto). HPLC grade methanol, trifluoroacetic acid, boric acid, etc. were purchased from Wako Pure Chemical Industries (Osaka). Water was purified using a Milli-Q gradient A10 system.

[0077] (3) animals

[0078] Animals were raised in an SPF environment under conditions of alternating light and dark every 12 hours, with free access to water and feed. C57BL / 6J mice were purchased from Japan Clear (Osaka).

[0079] (4) Renal ischemia-reperfusion treatment

[0080] Male mice aged 12-16 weeks were subjected to renal ischemia-reperfusion (hereinafter also referred to as "IRI") tre...

Embodiment 2

[0087] Example 2: Hypoxic stress on renal tubular epithelial cells (TEC)

[0088] mProx24 cells as mouse renal tubular epithelial cells were provided by Sugaya (St. Marianna University School of Medicine, Tokyo). The cells were cultured in DMEM medium supplemented with 5% fetal bovine serum (FBS) and 1% penicillin and streptomycin. The cultured cells were diluted with 1.0×10 DMEM medium supplemented with 1% FBS 6 Cells / well seeding at 37°C, 5% CO 2 and 20%O 2 Incubate for 24 hours under a humidified atmosphere. In the hypoxic stress group, after 24 hours of culture, in DMEM medium supplemented with 5% FBS in 5% CO 2 and 5%O 2 Further cultured in a humidified atmosphere for 20 hours, in the non-hypoxic stress group, in DMEM medium supplemented with 5% FBS in 5% CO 2 and 20%O 2 Further cultured for 20 hours in a humidified atmosphere ( Figure 4 (A)). 1 μM, 10 μM, and 100 μM of D-serine were added as a test drug to these DMEM media, and D-serine was not contained in t...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention pertains to a pharmaceutical composition for the prevention or treatment of kidney disease, an inflammation inhibitor for the kidneys, an inflammatory cell death inhibitor for the kidneys, or a food for the prevention or improvement of kidney disease, that include D-serine or a derivative thereof. In addition, the present invention pertains to the use of D-serine or a derivative thereof, for the production of a pharmaceutical composition for the prevention or treatment of kidney disease.

Description

technical field [0001] The present invention relates to a pharmaceutical composition for preventing or treating kidney damage, an inflammation inhibitor in the kidney, an inhibitor of inflammatory cell death, a food for preventing or improving kidney damage, and a kidney protecting agent. Background technique [0002] The kidney is an organ that maintains the stability of body fluids by filtering waste and excess water in the blood and excreting them as urine. In addition, it is an organ that regulates blood pressure, hematopoiesis, and bone metabolism through endocrine functions. Kidneys are damaged due to factors such as immune system abnormalities, drugs, high blood pressure, diabetes, bleeding and / or a sudden drop in blood pressure, infectious diseases, and dehydration associated with burns, resulting in reduced function. This state is called kidney disease, and kidney disease caused by diabetes is called diabetic nephropathy. [0003] Acute kidney injury (Acute Kidney ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/198A23L33/175A61P13/12A61P43/00
CPCA61P29/00A61P43/00A61P9/10A61P13/12A23L33/175A61K31/198A61K9/0019
Inventor 和田隆志古市贤吾坂井宣彦岩田恭宜原章规中出祐介浜濑健司三田真史
Owner KANAZAWA UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products